The studies on the concomitant diseases and combined medication in patients with onychomycosis

Chan Song Young, Joong Ahn Kyu, Ok Kim Hyung, Young Chul Kye, Ho Choi Jee, Wook Park Chun, Joong Kim Kwang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Oral terbinafine, itraconazole and fluconazole are the most common agents used for the treatment of toenail onychomycosis. However, these agents differ markedly in their potential to cause clinically significant drug interactions. Triazoles such as fluconazole and itraconazole have been responsible for a greater number of clinically significant drug interactions than terbinafine. Objective: We performed this survey to provide the information about how many patients with onychomycosis have concomitant diseases and combined medication and to gauge about the drug interaction risk of antifungal agent. Method: The findings presented in this report are based on total 569 onychomycosis patients, with KOH positive, who visited 6 university hospitals from February 2007 to March 2007. Result: The patients with onychomycosis had concomitant diseases (43.1%) and used combination medication (36.4%). The majority of the patient have concomitant diseases, such as hypertension (12.2%), diabetic melitus (9.5%) and hyperlipidemia (4.1%), more frequent in elderly patients. Main factor to choose antifungal agent for the cure of onychomycosis is the efficacy of the medication (55%), as well as, the safety and drug interaction risk of antifungal agent, more important in case of the patient taking a variety of concomitant drugs. Conclusion: It is concluded that physicians should be aware of the potential interaction of the medications in order to prevent or reduce the burden of adverse events. It is required to have more cautious choice of oral antifungal agent in those patients who are taking combined medications in patients with onycomycosis.

Original languageEnglish
Pages (from-to)163-172
Number of pages10
JournalKorean Journal of Medical Mycology
Volume12
Issue number3
Publication statusPublished - 2007 Sep 1

Fingerprint

Onychomycosis
terbinafine
Antifungal Agents
Drug Interactions
Itraconazole
Fluconazole
Triazoles
Nails
Hyperlipidemias
Hypertension
Physicians
Safety

Keywords

  • Combined medication
  • Concomitant disease
  • Fluconazole
  • Itraconazole
  • Onychomycosis
  • Terbinafine

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Young, C. S., Kyu, J. A., Hyung, O. K., Kye, Y. C., Jee, H. C., Chun, W. P., & Kwang, J. K. (2007). The studies on the concomitant diseases and combined medication in patients with onychomycosis. Korean Journal of Medical Mycology, 12(3), 163-172.

The studies on the concomitant diseases and combined medication in patients with onychomycosis. / Young, Chan Song; Kyu, Joong Ahn; Hyung, Ok Kim; Kye, Young Chul; Jee, Ho Choi; Chun, Wook Park; Kwang, Joong Kim.

In: Korean Journal of Medical Mycology, Vol. 12, No. 3, 01.09.2007, p. 163-172.

Research output: Contribution to journalArticle

Young, CS, Kyu, JA, Hyung, OK, Kye, YC, Jee, HC, Chun, WP & Kwang, JK 2007, 'The studies on the concomitant diseases and combined medication in patients with onychomycosis', Korean Journal of Medical Mycology, vol. 12, no. 3, pp. 163-172.
Young, Chan Song ; Kyu, Joong Ahn ; Hyung, Ok Kim ; Kye, Young Chul ; Jee, Ho Choi ; Chun, Wook Park ; Kwang, Joong Kim. / The studies on the concomitant diseases and combined medication in patients with onychomycosis. In: Korean Journal of Medical Mycology. 2007 ; Vol. 12, No. 3. pp. 163-172.
@article{dac9c08e8f934662be8162246387bdef,
title = "The studies on the concomitant diseases and combined medication in patients with onychomycosis",
abstract = "Background: Oral terbinafine, itraconazole and fluconazole are the most common agents used for the treatment of toenail onychomycosis. However, these agents differ markedly in their potential to cause clinically significant drug interactions. Triazoles such as fluconazole and itraconazole have been responsible for a greater number of clinically significant drug interactions than terbinafine. Objective: We performed this survey to provide the information about how many patients with onychomycosis have concomitant diseases and combined medication and to gauge about the drug interaction risk of antifungal agent. Method: The findings presented in this report are based on total 569 onychomycosis patients, with KOH positive, who visited 6 university hospitals from February 2007 to March 2007. Result: The patients with onychomycosis had concomitant diseases (43.1{\%}) and used combination medication (36.4{\%}). The majority of the patient have concomitant diseases, such as hypertension (12.2{\%}), diabetic melitus (9.5{\%}) and hyperlipidemia (4.1{\%}), more frequent in elderly patients. Main factor to choose antifungal agent for the cure of onychomycosis is the efficacy of the medication (55{\%}), as well as, the safety and drug interaction risk of antifungal agent, more important in case of the patient taking a variety of concomitant drugs. Conclusion: It is concluded that physicians should be aware of the potential interaction of the medications in order to prevent or reduce the burden of adverse events. It is required to have more cautious choice of oral antifungal agent in those patients who are taking combined medications in patients with onycomycosis.",
keywords = "Combined medication, Concomitant disease, Fluconazole, Itraconazole, Onychomycosis, Terbinafine",
author = "Young, {Chan Song} and Kyu, {Joong Ahn} and Hyung, {Ok Kim} and Kye, {Young Chul} and Jee, {Ho Choi} and Chun, {Wook Park} and Kwang, {Joong Kim}",
year = "2007",
month = "9",
day = "1",
language = "English",
volume = "12",
pages = "163--172",
journal = "Korean Journal of Medical Mycology",
issn = "1226-4709",
publisher = "Korean Society for Medical Mycology",
number = "3",

}

TY - JOUR

T1 - The studies on the concomitant diseases and combined medication in patients with onychomycosis

AU - Young, Chan Song

AU - Kyu, Joong Ahn

AU - Hyung, Ok Kim

AU - Kye, Young Chul

AU - Jee, Ho Choi

AU - Chun, Wook Park

AU - Kwang, Joong Kim

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Background: Oral terbinafine, itraconazole and fluconazole are the most common agents used for the treatment of toenail onychomycosis. However, these agents differ markedly in their potential to cause clinically significant drug interactions. Triazoles such as fluconazole and itraconazole have been responsible for a greater number of clinically significant drug interactions than terbinafine. Objective: We performed this survey to provide the information about how many patients with onychomycosis have concomitant diseases and combined medication and to gauge about the drug interaction risk of antifungal agent. Method: The findings presented in this report are based on total 569 onychomycosis patients, with KOH positive, who visited 6 university hospitals from February 2007 to March 2007. Result: The patients with onychomycosis had concomitant diseases (43.1%) and used combination medication (36.4%). The majority of the patient have concomitant diseases, such as hypertension (12.2%), diabetic melitus (9.5%) and hyperlipidemia (4.1%), more frequent in elderly patients. Main factor to choose antifungal agent for the cure of onychomycosis is the efficacy of the medication (55%), as well as, the safety and drug interaction risk of antifungal agent, more important in case of the patient taking a variety of concomitant drugs. Conclusion: It is concluded that physicians should be aware of the potential interaction of the medications in order to prevent or reduce the burden of adverse events. It is required to have more cautious choice of oral antifungal agent in those patients who are taking combined medications in patients with onycomycosis.

AB - Background: Oral terbinafine, itraconazole and fluconazole are the most common agents used for the treatment of toenail onychomycosis. However, these agents differ markedly in their potential to cause clinically significant drug interactions. Triazoles such as fluconazole and itraconazole have been responsible for a greater number of clinically significant drug interactions than terbinafine. Objective: We performed this survey to provide the information about how many patients with onychomycosis have concomitant diseases and combined medication and to gauge about the drug interaction risk of antifungal agent. Method: The findings presented in this report are based on total 569 onychomycosis patients, with KOH positive, who visited 6 university hospitals from February 2007 to March 2007. Result: The patients with onychomycosis had concomitant diseases (43.1%) and used combination medication (36.4%). The majority of the patient have concomitant diseases, such as hypertension (12.2%), diabetic melitus (9.5%) and hyperlipidemia (4.1%), more frequent in elderly patients. Main factor to choose antifungal agent for the cure of onychomycosis is the efficacy of the medication (55%), as well as, the safety and drug interaction risk of antifungal agent, more important in case of the patient taking a variety of concomitant drugs. Conclusion: It is concluded that physicians should be aware of the potential interaction of the medications in order to prevent or reduce the burden of adverse events. It is required to have more cautious choice of oral antifungal agent in those patients who are taking combined medications in patients with onycomycosis.

KW - Combined medication

KW - Concomitant disease

KW - Fluconazole

KW - Itraconazole

KW - Onychomycosis

KW - Terbinafine

UR - http://www.scopus.com/inward/record.url?scp=37549065186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549065186&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:37549065186

VL - 12

SP - 163

EP - 172

JO - Korean Journal of Medical Mycology

JF - Korean Journal of Medical Mycology

SN - 1226-4709

IS - 3

ER -